CG Oncology, Inc. Common stock (CGON)vsBeiGene, Ltd. (ONC)
CGON
CG Oncology, Inc. Common stock
$65.81
+3.09%
HEALTHCARE · Cap: $5.39B
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 132153% more annual revenue ($5.34B vs $4.04M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
CGON
Avoid32
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CGON.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
4.1% revenue growth
0.0% earnings growth
0.0% margin — thin
ROE of -21.7% — below average capital efficiency
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CGON
The strongest argument for CGON centers on Altman Z-Score.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : CGON
The primary concerns for CGON are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
CGON profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
CGON carries more volatility with a beta of 1.19 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 32/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology company focused on innovating cancer therapies, with its lead asset, CG0070, being an oncolytic virus therapy designed specifically for non-muscle invasive bladder cancer. The company's strategic commitment to addressing significant unmet needs in oncology emphasizes its potential impact on patient outcomes and treatment paradigms. As CG Oncology progresses through clinical trials and approaches key regulatory milestones, it leverages its proprietary platform to position itself favorably in the competitive oncology landscape. This strategic focus on pioneering therapeutic solutions presents a compelling opportunity for institutional investors seeking to invest in transformative advancements in cancer care.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?